Literature DB >> 27140709

Serum Procalcitonin for Differential Diagnosis of Acute Exacerbation and Bacterial Pneumonia in Patients With Interstitial Lung Disease.

Jae Kyeom Sim1, Jee Youn Oh1, Eun Joo Lee2, Gyu Young Hur1, Seung Heon Lee3, Sung Yong Lee1, Sang Yeub Lee2, Je Hyeong Kim3, Chol Shin3, Jae Jeong Shim1, Kwang Ho In2, Kyung Ho Kang1, Kyung Hoon Min4.   

Abstract

BACKGROUND: Acute exacerbation and bacterial pneumonia are major life-threatening conditions in patients with interstitial lung disease (ILD). The rapid recognition of these 2 different conditions is important for their proper treatment. An elevated procalcitonin (PCT) level is commonly detected in patients with bacterial infections. This study assessed the usefulness of the serum PCT level as a biomarker for the differential diagnosis of acute exacerbation and bacterial pneumonia in patients with ILD.
MATERIALS AND METHODS: In this prospective observational study, we enrolled patients with ILD who had experienced recently progressive dyspnea and exhibited new infiltrations on chest radiographs. We classified these patients into an acute exacerbation group and a bacterial pneumonia group and compared their baseline characteristics and laboratory parameters, including the PCT level.
RESULTS: Of 21 patients with ILD, 9 patients had bacterial pneumonia. Both the groups showed similar baseline characteristics. The bacterial pneumonia group demonstrated a high PCT level. The PCT level in the acute exacerbation group was significantly lower than that in the bacterial pneumonia group (0.05 versus 0.91ng/mL, respectively; P < 0.001). Other parameters, such as the C-reactive protein level, leukocyte count and body temperature, were also lower in the acute exacerbation group. At a cutoff value of 0.1ng/mL, the sensitivity, specificity and negative predictive values of the serum PCT level were 88.9%, 100.0% and 92.3%, respectively.
CONCLUSIONS: These findings suggest that the serum PCT level is useful in the differential diagnosis of acute exacerbation and bacterial pneumonia in patients with ILD.
Copyright © 2016 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacterial; Interstitial; Lung diseases; Pneumonia; Procalcitonin

Mesh:

Substances:

Year:  2016        PMID: 27140709     DOI: 10.1016/j.amjms.2016.02.029

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  3 in total

Review 1.  Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review.

Authors:  Jiho Jun; Sang-Ryung Lee; Ji Yean Lee; Min Joo Choi; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Joon Young Song
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

2.  Kinetics of Immunoglobulins in Septic Shock Patients Treated With an IgM- and IgA-Enriched Intravenous Preparation: An Observational Study.

Authors:  Giorgio Berlot; Alice Scamperle; Tatiana Istrati; Roberto Dattola; Irene Longo; Antonino Chillemi; Silvia Baronio; Giada Quarantotto; Silvia Zanchi; Erik Roman-Pognuz; Mattia Bixio; Ariella Tomasini
Journal:  Front Med (Lausanne)       Date:  2021-03-01

Review 3.  Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analysis Based on 10 Cohort Studies.

Authors:  Yue Shen; Cheng Cheng; Xue Zheng; Yuefei Jin; Guangcai Duan; Mengshi Chen; Shuaiyin Chen
Journal:  Medicina (Kaunas)       Date:  2021-06-09       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.